1. Home
  2. KORE vs SCYX Comparison

KORE vs SCYX Comparison

Compare KORE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KORE
  • SCYX
  • Stock Information
  • Founded
  • KORE 2003
  • SCYX 1999
  • Country
  • KORE United States
  • SCYX United States
  • Employees
  • KORE N/A
  • SCYX N/A
  • Industry
  • KORE Telecommunications Equipment
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KORE Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • KORE Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • KORE 44.4M
  • SCYX 40.9M
  • IPO Year
  • KORE N/A
  • SCYX 2014
  • Fundamental
  • Price
  • KORE $2.52
  • SCYX $0.98
  • Analyst Decision
  • KORE Buy
  • SCYX Buy
  • Analyst Count
  • KORE 2
  • SCYX 1
  • Target Price
  • KORE $10.00
  • SCYX N/A
  • AVG Volume (30 Days)
  • KORE 9.8K
  • SCYX 129.0K
  • Earning Date
  • KORE 05-14-2025
  • SCYX 03-12-2025
  • Dividend Yield
  • KORE N/A
  • SCYX N/A
  • EPS Growth
  • KORE N/A
  • SCYX N/A
  • EPS
  • KORE N/A
  • SCYX N/A
  • Revenue
  • KORE $285,229,000.00
  • SCYX $3,746,000.00
  • Revenue This Year
  • KORE $3.89
  • SCYX $1,541.00
  • Revenue Next Year
  • KORE $5.35
  • SCYX $111.43
  • P/E Ratio
  • KORE N/A
  • SCYX N/A
  • Revenue Growth
  • KORE 7.01
  • SCYX N/A
  • 52 Week Low
  • KORE $1.10
  • SCYX $0.82
  • 52 Week High
  • KORE $4.88
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • KORE 52.81
  • SCYX 43.38
  • Support Level
  • KORE $2.40
  • SCYX $1.00
  • Resistance Level
  • KORE $2.60
  • SCYX $1.06
  • Average True Range (ATR)
  • KORE 0.16
  • SCYX 0.07
  • MACD
  • KORE -0.00
  • SCYX 0.00
  • Stochastic Oscillator
  • KORE 72.73
  • SCYX 41.99

About KORE KORE Group Holdings Inc.

Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates a majority of its revenue from the United States and the rest from other countries.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: